Search bioRxiv⌕ Search

Biology subjects

Haeryfar, S. M. M.

Publications and source records attributed to Haeryfar, S. M. M..

4 recordsLinked to original sources

Characterizing and Mitigating Protocol-Dependent Gene Expression Bias in 3' and 5' Single-Cell RNA Sequencing

Single-cell RNA sequencing (scRNA-seq) has enabled large-scale characterization of cellular heterogeneity; yet, integrating datasets generated through different library preparation protocols remains challenging. For instance, comparisons between 10X Genomics 3' and 5' chemistries are complicated by protocol-dependent technical biases imposed by differences in transcript end capture and amplification. While normalization, and often batch correction, is an integral step in preprocessing scRNA-seq datasets, it remains unclear which correction is most appropriate, or even necessary, for reliable cross-protocol comparisons. Here, we systematically characterize protocol-related expression differences using 35 matched donors across six tissues profiled with both 3' and 5' scRNA-seq approaches. We find that gene expression discrepancies are not pervasive across the whole transcriptome, but driven instead by a relatively small, reproducible subset of protocol-biased genes. Excluding these genes improves cross-protocol concordance, indicating that most genes are directly comparable without aggressive correction. We then benchmark commonly employed normalization approaches and show that while several methods, such as fastMNN, improve statistical alignment when cell populations are well matched, they can distort gene-level signals and inflate differential expression in biologically realistic settings with incomplete cell-type overlap. Taken together, our results demonstrate that protocol bias between 3' and 5' scRNA-seq is limited in scope and that targeted handling of a small set of biased genes presents an alternative approach to normalization or batch correction strategies. This work provides a practical guideline for integrating 3' and 5' scRNA-seq data and highlights the importance of matching normalization strategies to the structure of technical variation and the intended downstream analyses.

bioinformatics↗

Homocitrullinated Peptides Drive Pro-Inflammatory T-Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

ObjectiveAnti-homocitrullinated protein/peptide antibodies (AHCPA) are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated antigens. However, T-cell responses to homocitrullinated peptides remain largely unexplored. We investigated these responses in a humanized HLA-DR4-transgenic (DR4tg) mouse model of RA, which expresses the strongest genetic risk factor for this disease. MethodsDR4tg mice were injected subcutaneously with a homocitrullinated peptide called HomoCitJED while control mice received phosphate-buffered saline. After 10 days, T-cells were analyzed for their phenotypic characteristics, cytokine production, and proliferative capacities in the draining lymph nodes (dLNs) and spleens by flow cytometry, enzyme-linked immunosorbent assays, and ProQuantum immunoassays. ResultsHomoCitJED immunization drove robust expansion of T helper (Th) 1, Th17 and hybrid Th1/Th17 CD4+ T cells in dLNs, alongside elevated CD25 activation marker within these subsets. Intracellular cytokine staining confirmed effector activity, revealing higher frequencies of IL-17A+, TNF-+IL-17A+, and IFN-{gamma}+IL-17A+ CD4+ T cells. CD4+ T cells from dLNs also up-regulated the exhaustion markers LAG-3 and Tim-3. CD8+ T cells (Tc) mirrored these findings, as HomoCitJED immunization augmented CD25 and KLRG1 expression, Tc1/Tc17-type IL-17A and IFN-{gamma}/IL-17A production, and antigen-specific proliferation. Additionally, Tim-3, LAG-3 and PD-1 expression on these subsets was augmented. ConclusionsA homocitrullinated peptide elicited Th1/Th17 and Tc1/Tc17 responses marked by concurrent activation and exhaustion signatures, pointing to a dysregulated T-cell state. These findings position homocitrulline-driven T-cell imbalance across both CD4+ and CD8+ T-cell compartments as a potential mechanistic contributor to RA pathogenesis and a target for future immunomodulatory therapies.

immunology↗

Targeting the MR1-MAIT Cell Axis Improves Vaccine Efficacy and Affords Protection against Viral Pathogens

Mucosa-associated invariant T (MAIT) cells are MR1-restricted, innate-like T lymphocytes with tremendous antibacterial and immunomodulatory functions. MAIT cells also sense and respond to viral infections in an MR1-independent fashion. However, whether they can be directly targeted in immunization strategies against viral pathogens is unknown. We addressed this question in multiple wild-type and genetically altered but clinically relevant mouse strains using several vaccine platforms against influenza viruses, poxviruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We demonstrate that 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU), a riboflavin-based MR1 ligand of bacterial origin, can synergize with viral vaccines to expand MAIT cells in multiple tissues, reprogram them towards a pro-inflammatory MAIT1 phenotype, license them to bolster mainstream virus-specific CD8+ T cell responses, and potentiate heterosubtypic antiviral protection. Repeated 5-OP-RU administration did not render MAIT cells anergic, thus allowing for its inclusion in prime-boost immunization protocols. Mechanistically, tissue MAIT cell accumulation was due to their robust proliferation, as opposed to altered migratory behavior, and required viral vaccine replication competency, Toll-like receptor 3 (TLR3) and cell-autonomous type I interferon receptor signaling. Furthermore, the observed phenomenon was manifest in young and old female and male mice, and could also be recapitulated in a human cell culture system in which peripheral blood mononuclear cells were exposed to replicating virions and 5-OP-RU. In conclusion, although viruses and virus-based vaccines are devoid of the riboflavin biosynthesis machinery that supplies MR1 ligands, targeting MR1 enhances the efficacy of vaccine-elicited antiviral immunity. We propose 5-OP-RU as a non-classic but potent and versatile vaccine adjuvant against respiratory viruses.

immunology↗

Monovalent and trivalent VSV-based COVID-19 vaccines elicit potent neutralizing antibodies and immunodominant CD8+ T cells against diverse SARS-CoV-2 variants

Recombinant vesicular stomatitis virus (rVSV) vaccines expressing Spike proteins of Wuhan, Beta and/or Delta variants of SARS-CoV-2 were generated and tested for induction of antibody and T cell immune responses in mice. rVSV-Wuhan and rVSV-Delta vaccines and a rVSV-Trivalent (mixed rVSV-Wuhan, -Beta, -Delta) vaccine elicited potent neutralizing antibodies (nAbs) against live SARS-CoV-2 Wuhan (USAWA1), Beta (B.1.351), Delta (B.1.617.2) and Omicron (B.1.1.529) viruses. Prime-boost vaccination with rVSV-Beta was less effective in this capacity. Heterologous boosting of rVSV-Wuhan with rVSV-Delta induced strong nAb responses against Delta and Omicron viruses, with rVSV-Trivalent vaccine consistently effective in inducing nAbs against all the SARS-CoV-2 variants tested. All vaccines, including rVSV-Beta, elicited a spike-specific immunodominant CD8+ T cell response. Collectively, rVSV vaccines targeting SARS-CoV-2 variants of concern may be considered in the global fight against COVID-19.

immunology↗